A
adreogen
adreogen.com
Website unreachable since Oct 19, 2026
The startup develops topical androgen therapies that specifically target Relapse-Initiating Cells (RICs) in leukemia patients to prevent drug resistance and relapse. By focusing on these critical cells, the therapies aim to enhance patient health outcomes and improve overall treatment efficacy.
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops topical androgen therapies that specifically target Relapse-Initiating Cells (RICs) in leukemia patients to prevent drug resistance and relapse. By focusing on these critical cells, the therapies aim to enhance patient health outcomes and improve overall treatment efficacy.